Special Issue "Tumor Radioresistance"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 April 2019
Prof. Dr. Jan Bussink
Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
Website | E-Mail
Interests: Radioresistance; tumor microenvironment; tumor cell hypoxia; EGFR signaling; tumor cell metabolism; tumor vasculature; non-invasive PET imaging; lung cancer
Radiotherapy is given to a majority of patients with cancer, and remains one of the most (cost)effective treatment options available. However, several mechanisms attenuating the efficacy of tumor irradiation have long been known to occur, such as hypoxia, DNA damage repair, repopulation and cell cycle redistribution. Radiobiology research into tumor radioresistance has thus focused on targeting these mechanisms to increase radiotherapy effectiveness by e.g. hypoxia modification, or using combination therapy with DNA damage repair or growth factor receptor inhibitors and reducing the overall treatment time.
The impact of some of these classic mechanisms on tumor radioresistance has changed, however, with the widespread use of novel radiotherapy regimens such as heavy ions/particles, stereotactic radiotherapy, radiotherapy and immunotherapy combination, etc.. Additionally, recent insights in additional mechanisms such as stem cells/stemness, tumor metabolism, and effect of irradiation on the immune system has lead to rapid development of additional targets for combination therapy with irradiation.
We aim to describe these new aspects identifying and overcoming tumor radioresistance in this Special Issue of Cancers, and welcome all contributions to this field.
Prof. Dr. Jan Bussink
Dr. Paul Span
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- DNA damage repair
- Radiotherapy-immunotherapy combinations
- Stem cells
- Tumor cell proliferation